MDR1/P-GP Expression as A Prognostic Factor in Acute Leukemias View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

1999

AUTHORS

Jean-Pierre Marie , Ollivier Legrand

ABSTRACT

P-glycoprotein (P-gp) is often expressed (40–50%) on leukemic cells at diagnosis in acute myelogenous leukemia (AML), and is even more frequently present after treatment failure. Several large cohorts of newly diagnosed AML patients treated with a classical anthracycline + standard doses of cytosine arabinoside were tested for the prognosis value of MDR1 phenotype, and demonstrated an high correlation between a significant increase of MDR1 gene expression and treatment failure (or, better, drug resistance).This P-gp(+) drug resistance could be due either to a particular phenotype of bad prognosis AML, as it is suggested by the association of myelodysplasia, complex karyo-type and advanced age with MDR1 phenotype, or due primarily to the active efflux of anthracyclines and VP16 in P-gp (+) leukemic cells. Several observations tend to confirm the functional role of the P-gp in clinical drug resistance: (i) using multivariate analysis, MDR1 phenotype appears to be an independent variable, as potent (or higher) as karyo-type and age for predicting in vivo drug resistance; (ii) the prognostic value is limited to the CD34(+)/P-gp(+) phenotype, wich is linked to a functional P-gp; (iii) the in vitro sensitivity to anthracyclines and VP16 is highly correlated with P-gp expression. All these data argue for an early use of P-gp modifier agents in the treatment of AML.The role of the MDR1 gene in ALL resistance is controversial and marginal compared to the sensitivity of ALL blasts to glucocorticoids, and the frequency of MDR1 phenotype is low at diagnosis, and is increasing only after repetitive chemotherapies. More... »

PAGES

1-9

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_1

DOI

http://dx.doi.org/10.1007/978-1-4615-4811-9_1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050675331

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10500774


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP Binding Cassette Transporter, Subfamily B, Member 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, MDR", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Failure", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service d\u2019H\u00e9matologie Biologique de l\u2019H\u00f4tel-Dieu Formation de Recherche Associ\u00e9 Claude Bernard, Universit\u00e9 Paris VI. H\u00f4tel-Dieu, 75181, Paris Cedex 04, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service d\u2019H\u00e9matologie Biologique de l\u2019H\u00f4tel-Dieu Formation de Recherche Associ\u00e9 Claude Bernard, Universit\u00e9 Paris VI. H\u00f4tel-Dieu, 75181, Paris Cedex 04, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marie", 
        "givenName": "Jean-Pierre", 
        "id": "sg:person.01064502270.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064502270.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service d\u2019H\u00e9matologie Biologique de l\u2019H\u00f4tel-Dieu Formation de Recherche Associ\u00e9 Claude Bernard, Universit\u00e9 Paris VI. H\u00f4tel-Dieu, 75181, Paris Cedex 04, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service d\u2019H\u00e9matologie Biologique de l\u2019H\u00f4tel-Dieu Formation de Recherche Associ\u00e9 Claude Bernard, Universit\u00e9 Paris VI. H\u00f4tel-Dieu, 75181, Paris Cedex 04, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legrand", 
        "givenName": "Ollivier", 
        "id": "sg:person.0752753564.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1999", 
    "datePublishedReg": "1999-01-01", 
    "description": "P-glycoprotein (P-gp) is often expressed (40\u201350%) on leukemic cells at diagnosis in acute myelogenous leukemia (AML), and is even more frequently present after treatment failure. Several large cohorts of newly diagnosed AML patients treated with a classical anthracycline + standard doses of cytosine arabinoside were tested for the prognosis value of MDR1 phenotype, and demonstrated an high correlation between a significant increase of MDR1 gene expression and treatment failure (or, better, drug resistance).This P-gp(+) drug resistance could be due either to a particular phenotype of bad prognosis AML, as it is suggested by the association of myelodysplasia, complex karyo-type and advanced age with MDR1 phenotype, or due primarily to the active efflux of anthracyclines and VP16 in P-gp (+) leukemic cells. Several observations tend to confirm the functional role of the P-gp in clinical drug resistance: (i) using multivariate analysis, MDR1 phenotype appears to be an independent variable, as potent (or higher) as karyo-type and age for predicting in vivo drug resistance; (ii) the prognostic value is limited to the CD34(+)/P-gp(+) phenotype, wich is linked to a functional P-gp; (iii) the in vitro sensitivity to anthracyclines and VP16 is highly correlated with P-gp expression. All these data argue for an early use of P-gp modifier agents in the treatment of AML.The role of the MDR1 gene in ALL resistance is controversial and marginal compared to the sensitivity of ALL blasts to glucocorticoids, and the frequency of MDR1 phenotype is low at diagnosis, and is increasing only after repetitive chemotherapies.", 
    "editor": [
      {
        "familyName": "Kaspers", 
        "givenName": "G. J. L.", 
        "type": "Person"
      }, 
      {
        "familyName": "Pieters", 
        "givenName": "R.", 
        "type": "Person"
      }, 
      {
        "familyName": "Veerman", 
        "givenName": "A. J. P.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4615-4811-9_1", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4613-7180-9", 
        "978-1-4615-4811-9"
      ], 
      "name": "Drug Resistance in Leukemia and Lymphoma III", 
      "type": "Book"
    }, 
    "keywords": [
      "acute myelogenous leukemia", 
      "MDR1 phenotype", 
      "drug resistance", 
      "treatment failure", 
      "gp expression", 
      "leukemic cells", 
      "treatment of AML", 
      "vivo drug resistance", 
      "MDR1/P", 
      "clinical drug resistance", 
      "MDR1 gene expression", 
      "repetitive chemotherapy", 
      "standard doses", 
      "prognostic factors", 
      "AML patients", 
      "prognostic value", 
      "acute leukemia", 
      "advanced age", 
      "large cohort", 
      "myelogenous leukemia", 
      "prognosis value", 
      "multivariate analysis", 
      "MDR1 gene", 
      "early use", 
      "classical anthracyclines", 
      "anthracyclines", 
      "significant increase", 
      "active efflux", 
      "leukemia", 
      "diagnosis", 
      "phenotype", 
      "age", 
      "functional role", 
      "GPs", 
      "expression", 
      "gene expression", 
      "cells", 
      "chemotherapy", 
      "patients", 
      "myelodysplasia", 
      "failure", 
      "particular phenotype", 
      "glucocorticoids", 
      "cohort", 
      "doses", 
      "VP16", 
      "treatment", 
      "resistance", 
      "high correlation", 
      "role", 
      "association", 
      "efflux", 
      "independent variables", 
      "sensitivity", 
      "glycoprotein", 
      "agents", 
      "blasts", 
      "factors", 
      "genes", 
      "increase", 
      "correlation", 
      "cytosine", 
      "use", 
      "frequency", 
      "values", 
      "data", 
      "variables", 
      "analysis", 
      "modifier agent", 
      "observations", 
      "wich"
    ], 
    "name": "MDR1/P-GP Expression as A Prognostic Factor in Acute Leukemias", 
    "pagination": "1-9", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050675331"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4615-4811-9_1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10500774"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4615-4811-9_1", 
      "https://app.dimensions.ai/details/publication/pub.1050675331"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-06-01T22:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/chapter/chapter_363.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4615-4811-9_1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-4811-9_1'


 

This table displays all metadata directly associated to this object as RDF triples.

200 TRIPLES      23 PREDICATES      110 URIs      103 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4615-4811-9_1 schema:about N2ab117b8260e4fcfb1785d471ecfdf6a
2 N30f5239d4aaa44f680a0acd01dcbbabd
3 N741d62230f204ff68d410d6912f34e94
4 Na4472406b45443e08e303e2a51029f08
5 Na87d7a26760140c496f7b7d74680ac9b
6 Nab6ee2d96d9146a78d9df8f123054cd8
7 Nc8c20e41965749f6930a9a512874ca2e
8 Ncfa3d272165349c89cc55f95dbdb42a2
9 Nd164d6fb9e9f441fa91be5374eca8f86
10 Nd1a32673c1b44934805d1ff9c3dc3e82
11 Nd905f2b02c26455d8549aed3a60e382a
12 Nec4c7e5a2e6e41298566ad83f718a616
13 anzsrc-for:11
14 anzsrc-for:1102
15 schema:author N906d8e56aed94593a047ec9fb4a65458
16 schema:datePublished 1999
17 schema:datePublishedReg 1999-01-01
18 schema:description P-glycoprotein (P-gp) is often expressed (40–50%) on leukemic cells at diagnosis in acute myelogenous leukemia (AML), and is even more frequently present after treatment failure. Several large cohorts of newly diagnosed AML patients treated with a classical anthracycline + standard doses of cytosine arabinoside were tested for the prognosis value of MDR1 phenotype, and demonstrated an high correlation between a significant increase of MDR1 gene expression and treatment failure (or, better, drug resistance).This P-gp(+) drug resistance could be due either to a particular phenotype of bad prognosis AML, as it is suggested by the association of myelodysplasia, complex karyo-type and advanced age with MDR1 phenotype, or due primarily to the active efflux of anthracyclines and VP16 in P-gp (+) leukemic cells. Several observations tend to confirm the functional role of the P-gp in clinical drug resistance: (i) using multivariate analysis, MDR1 phenotype appears to be an independent variable, as potent (or higher) as karyo-type and age for predicting in vivo drug resistance; (ii) the prognostic value is limited to the CD34(+)/P-gp(+) phenotype, wich is linked to a functional P-gp; (iii) the in vitro sensitivity to anthracyclines and VP16 is highly correlated with P-gp expression. All these data argue for an early use of P-gp modifier agents in the treatment of AML.The role of the MDR1 gene in ALL resistance is controversial and marginal compared to the sensitivity of ALL blasts to glucocorticoids, and the frequency of MDR1 phenotype is low at diagnosis, and is increasing only after repetitive chemotherapies.
19 schema:editor N7c95510ad2d54342b8a075465ffef20f
20 schema:genre chapter
21 schema:inLanguage en
22 schema:isAccessibleForFree false
23 schema:isPartOf Na2f7a0238da844308f138bf16ce95df4
24 schema:keywords AML patients
25 GPs
26 MDR1 gene
27 MDR1 gene expression
28 MDR1 phenotype
29 MDR1/P
30 VP16
31 active efflux
32 acute leukemia
33 acute myelogenous leukemia
34 advanced age
35 age
36 agents
37 analysis
38 anthracyclines
39 association
40 blasts
41 cells
42 chemotherapy
43 classical anthracyclines
44 clinical drug resistance
45 cohort
46 correlation
47 cytosine
48 data
49 diagnosis
50 doses
51 drug resistance
52 early use
53 efflux
54 expression
55 factors
56 failure
57 frequency
58 functional role
59 gene expression
60 genes
61 glucocorticoids
62 glycoprotein
63 gp expression
64 high correlation
65 increase
66 independent variables
67 large cohort
68 leukemia
69 leukemic cells
70 modifier agent
71 multivariate analysis
72 myelodysplasia
73 myelogenous leukemia
74 observations
75 particular phenotype
76 patients
77 phenotype
78 prognosis value
79 prognostic factors
80 prognostic value
81 repetitive chemotherapy
82 resistance
83 role
84 sensitivity
85 significant increase
86 standard doses
87 treatment
88 treatment failure
89 treatment of AML
90 use
91 values
92 variables
93 vivo drug resistance
94 wich
95 schema:name MDR1/P-GP Expression as A Prognostic Factor in Acute Leukemias
96 schema:pagination 1-9
97 schema:productId N7e93c275a11b4ce4af9fbac360510e7b
98 Na92fd4f1350b46d99daf242be796975f
99 Ncd5c8d2f4a934c2a9a787e8997faf014
100 schema:publisher Nd96e8278e062430c978bf76e95cc0dff
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050675331
102 https://doi.org/10.1007/978-1-4615-4811-9_1
103 schema:sdDatePublished 2022-06-01T22:33
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N3164c50cbbb24b6bb04d3f6bcee814c4
106 schema:url https://doi.org/10.1007/978-1-4615-4811-9_1
107 sgo:license sg:explorer/license/
108 sgo:sdDataset chapters
109 rdf:type schema:Chapter
110 N0ebd9a99e0674f1bb4757d50c205a738 schema:familyName Veerman
111 schema:givenName A. J. P.
112 rdf:type schema:Person
113 N29488d4bd3484b5c8d21fbcfecbe365f rdf:first N894da5e1d13f4c9691e1ceffab6c4311
114 rdf:rest N795ed0a070de4dfb91768488044aa180
115 N2ab117b8260e4fcfb1785d471ecfdf6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Leukemia, Myeloid, Acute
117 rdf:type schema:DefinedTerm
118 N30f5239d4aaa44f680a0acd01dcbbabd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Precursor Cell Lymphoblastic Leukemia-Lymphoma
120 rdf:type schema:DefinedTerm
121 N3164c50cbbb24b6bb04d3f6bcee814c4 schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 N741d62230f204ff68d410d6912f34e94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Acute Disease
125 rdf:type schema:DefinedTerm
126 N795ed0a070de4dfb91768488044aa180 rdf:first N0ebd9a99e0674f1bb4757d50c205a738
127 rdf:rest rdf:nil
128 N7c95510ad2d54342b8a075465ffef20f rdf:first Ndf3534aca6ca4574bb62d85fae85de85
129 rdf:rest N29488d4bd3484b5c8d21fbcfecbe365f
130 N7e93c275a11b4ce4af9fbac360510e7b schema:name pubmed_id
131 schema:value 10500774
132 rdf:type schema:PropertyValue
133 N894da5e1d13f4c9691e1ceffab6c4311 schema:familyName Pieters
134 schema:givenName R.
135 rdf:type schema:Person
136 N906d8e56aed94593a047ec9fb4a65458 rdf:first sg:person.01064502270.46
137 rdf:rest Nc6f7ebd2f59b40e3b50375c090b633b9
138 Na2f7a0238da844308f138bf16ce95df4 schema:isbn 978-1-4613-7180-9
139 978-1-4615-4811-9
140 schema:name Drug Resistance in Leukemia and Lymphoma III
141 rdf:type schema:Book
142 Na4472406b45443e08e303e2a51029f08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Leukemia
144 rdf:type schema:DefinedTerm
145 Na87d7a26760140c496f7b7d74680ac9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Humans
147 rdf:type schema:DefinedTerm
148 Na92fd4f1350b46d99daf242be796975f schema:name dimensions_id
149 schema:value pub.1050675331
150 rdf:type schema:PropertyValue
151 Nab6ee2d96d9146a78d9df8f123054cd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Child
153 rdf:type schema:DefinedTerm
154 Nc6f7ebd2f59b40e3b50375c090b633b9 rdf:first sg:person.0752753564.08
155 rdf:rest rdf:nil
156 Nc8c20e41965749f6930a9a512874ca2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name ATP Binding Cassette Transporter, Subfamily B, Member 1
158 rdf:type schema:DefinedTerm
159 Ncd5c8d2f4a934c2a9a787e8997faf014 schema:name doi
160 schema:value 10.1007/978-1-4615-4811-9_1
161 rdf:type schema:PropertyValue
162 Ncfa3d272165349c89cc55f95dbdb42a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Prognosis
164 rdf:type schema:DefinedTerm
165 Nd164d6fb9e9f441fa91be5374eca8f86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Antineoplastic Combined Chemotherapy Protocols
167 rdf:type schema:DefinedTerm
168 Nd1a32673c1b44934805d1ff9c3dc3e82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Adult
170 rdf:type schema:DefinedTerm
171 Nd905f2b02c26455d8549aed3a60e382a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Genes, MDR
173 rdf:type schema:DefinedTerm
174 Nd96e8278e062430c978bf76e95cc0dff schema:name Springer Nature
175 rdf:type schema:Organisation
176 Ndf3534aca6ca4574bb62d85fae85de85 schema:familyName Kaspers
177 schema:givenName G. J. L.
178 rdf:type schema:Person
179 Nec4c7e5a2e6e41298566ad83f718a616 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Treatment Failure
181 rdf:type schema:DefinedTerm
182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
183 schema:name Medical and Health Sciences
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
186 schema:name Cardiorespiratory Medicine and Haematology
187 rdf:type schema:DefinedTerm
188 sg:person.01064502270.46 schema:affiliation grid-institutes:None
189 schema:familyName Marie
190 schema:givenName Jean-Pierre
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064502270.46
192 rdf:type schema:Person
193 sg:person.0752753564.08 schema:affiliation grid-institutes:None
194 schema:familyName Legrand
195 schema:givenName Ollivier
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08
197 rdf:type schema:Person
198 grid-institutes:None schema:alternateName Service d’Hématologie Biologique de l’Hôtel-Dieu Formation de Recherche Associé Claude Bernard, Université Paris VI. Hôtel-Dieu, 75181, Paris Cedex 04, France
199 schema:name Service d’Hématologie Biologique de l’Hôtel-Dieu Formation de Recherche Associé Claude Bernard, Université Paris VI. Hôtel-Dieu, 75181, Paris Cedex 04, France
200 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...